PT-141: Side Effects & Safety

PT-141 (bremelanotide) is a melanocortin-receptor agonist approved by the FDA on June 21, 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.^[1] It is one of the very few peptides on this site with full FDA-approved Phase 3 safety data: over 1,200 participants across the RECONNECT-1 and RECONNECT-2 trials, plus a long-term open-label extension.^[2]

The safety profile is well-characterized: a high rate of nausea (40%), a transient blood-pressure elevation that limits use in cardiovascular disease, and a cumulative hyperpigmentation risk that drives the FDA's strict ≤8 doses/month limit. Outside the FDA-approved indication and dosage, PT-141 is sold for "research" purposes and these limits are often ignored — this is the most common source of harm.

PT-141 is not on the agenda for the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list meeting. It is already FDA-approved as Vyleesi for women with HSDD; off-label use in men or for general sexual enhancement is not FDA-approved.

Frequencies below are from the RECONNECT trials pooled population.^[2]

Effect	Frequency	Severity / Notes
Nausea	40%	Dose-limiting; most common in first few uses; severity often decreases over time
Flushing	20%	Facial and body warmth from melanocortin receptor activation
Injection-site reactions	13%	Mild redness, soreness; usually transient
Headache	11%	Often resolves with subsequent doses
Vomiting	~5%	Usually associated with severe nausea
Cough	3%	Class effect, mechanism unclear
Hyperpigmentation (focal or generalized)	1% with ≤8 doses/month; higher with more frequent dosing	May not fully reverse on discontinuation, especially in darker-pigmented skin or pre-existing nevi
Transient blood-pressure increase	Mean +1.9/1.7 mmHg over 24 hours post-dose; peak +6/3 mmHg at 4 hours	Heart rate decreases by ~5 bpm during the same window
Severe hypertensive episode	Rare	Possible especially in uncontrolled baseline hypertension
Discontinuation due to adverse effects	~18%	Mostly nausea-driven

PT-141 produces a transient increase in blood pressure peaking around 2–4 hours after subcutaneous dosing, with a parallel small decrease in heart rate. In healthy individuals, the changes are small and well-tolerated. In patients with cardiovascular disease, even small BP changes can be clinically significant.

• Contraindicated: uncontrolled hypertension and known cardiovascular disease (per FDA Vyleesi label).
• Caution: any baseline BP > 130/85 — check BP before initiation and at intervals.
• Concomitant antihypertensives: generally safe but monitor BP carefully during dose initiation.
• Driving / operating heavy machinery within 4–6 hours of dosing: use caution due to flushing, nausea, and BP changes.

PT-141 activates melanocortin receptors including MC1R on melanocytes. Frequent dosing produces dose-cumulative skin darkening — focal hyperpigmentation of the face, gums, breasts, and pre-existing nevi, or generalized darkening. This is the basis for the FDA's maximum 8 doses per month and minimum 24-hour interval between doses on the Vyleesi label.^[1]

Risk factors:

• Darker pre-existing skin pigmentation (Fitzpatrick IV–VI).
• Pre-existing nevi (moles) — may darken or change appearance.
• Frequency > 8 doses/month.
• Failure to discontinue when darkening starts.

Importantly, hyperpigmentation may not fully reverse on discontinuation in some patients. Existing nevi that darken should be evaluated by dermatology — new or changing nevi in melanotan-class peptide users are the most consistently reported serious cosmetic concern in this class. See our Melanotan II side effects page for more on the melanocortin agonist class.

• Uncontrolled hypertension or known cardiovascular disease (FDA contraindication).
• Concurrent naltrexone: PT-141 may reduce naltrexone plasma exposure by ~14%, which can compromise opioid-use-disorder treatment efficacy. The FDA label warns against this combination.
• Pregnancy: contraindicated. Animal data shows reproductive risk.
• Breastfeeding: not recommended; insufficient data on lactation transfer.
• Known hypersensitivity to bremelanotide.
• Active melanoma or atypical nevi: relative contraindication — discuss with dermatology.
• Severe hepatic or renal impairment: exposure may be increased; use caution.

Other drug interactions

• Oral medications: PT-141 slows gastric emptying. Time critical oral medications carefully or consider alternative timing.
• Alpha-adrenergic agonists / decongestants: theoretical additive BP effect.
• Other MSH-analog peptides (melanotan-I, melanotan-II): do not combine — additive hyperpigmentation and BP risk.

• Persistent nausea: reduce dose, take with food, dose later in the day to allow sleep through GI effects, or reduce frequency. Antiemetics (e.g., ondansetron) before dosing have been used off-label.
• BP elevation: discontinue and have BP evaluated. Do not resume in patients with confirmed elevated cardiovascular risk.
• Skin darkening: reduce frequency to ≤4 doses/month or discontinue. Have any new or changing nevi evaluated by dermatology immediately.
• Severe headache or vision change after dosing: seek emergency evaluation — rule out hypertensive emergency.
• Allergic reaction: discontinue immediately and seek emergency care.

See the PT-141 complete guide, dosage protocols, benefits and research, and the peptides for sexual health overview.